Quintiles announced that it has entered into a clinical pharmacology alliance with AstraZeneca to deliver AstraZeneca’s clinical pharmacology studies across multiple therapy areas and around the globe.
According to a release, Quintiles will assume the operational responsibilities for the majority of AstraZeneca’s clinical pharmacology delivery. The alliance is extensive and involves the engagement of a sole provider for clinical pharmacology delivery, and a simple, standardized pricing model. Also, as well as clinical conduct and medical oversight of studies, the agreement covers a range of activities across the end-to-end study process.
Quintiles’ network of clinical pharmacology facilities are located across Europe and the United States, with plans to open a unit in Asia in 2010. These facilities are connected via integrated data platforms using advanced electronic data capture and reporting.
An article that appeared in our June issue, based on a survey of CROs and Pharma managers, discussed this topic of changing relationship structures.
Another example of strategic alliances is between Covance and Lilly from last summer, where Covance took on Lilly’s non-GLP toxicology, in vivo pharmacology, quality control laboratory, and imaging services, and Lilly signed to provide Covance $1.6B in services over 10 years.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.